The Potential Impact of CAR T-Cell Treatment Delays on Society
Treatment delays limit the social value generated by chimeric antigen receptor (CAR) T-cell therapy for the treatment of pediatric acute lymphoblastic leukemia and diffuse large B-cell lymphoma.
The Well-Being of Long-Term Cancer Survivors
This study compares the well-being of long-term cancer survivors with that of US residents of similar age and demographic characteristics, patients recently diagnosed with cancer, and individuals with chronic illness.
The Option Value of Innovative Treatments for Non–Small Cell Lung Cancer and Renal Cell Carcinoma
Option value is the benefit a therapy provides patients by enabling them to survive to the next innovation.
2 Clarke Drive Cranbury, NJ 08512